Kazia Therapeutics (KZIA) Other Non-Current Liabilities (2009 - 2025)

Kazia Therapeutics has reported Other Non-Current Liabilities for 15 years, with the latest figure at $5047.1 in Q4 2025.

• For the quarter ending Q4 2025, Other Non-Current Liabilities fell 99.78% year-over-year to $5047.1; the trailing twelve-month figure through Dec 2025 stood at $5047.1 (down 99.78% YoY), and the FY2025 full-year result was $4923.0, down 99.8% from the prior year.
• Other Non-Current Liabilities for Q4 2025 stood at $5047.1, up from $4923.0 in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $6.9 million in Q2 2021, with the low at $4923.0 in Q2 2025.
• Historically, Other Non-Current Liabilities has averaged $3.1 million across 5 years, with a median of $3.0 million in 2023.
• Annual changes were most pronounced in 2021 — Other Non-Current Liabilities jumped 2190.03% — and 2025, when it plunged 99.8%.
• Kazia Therapeutics' Other Non-Current Liabilities stood at $568165.0 in 2021, then soared by 838.8% to $5.3 million in 2022, then slumped by 32.14% to $3.6 million in 2023, then tumbled by 36.49% to $2.3 million in 2024, then slumped by 99.78% to $5047.1 in 2025.
• The last three Other Non-Current Liabilities figures came in at $5047.1 (Q4 2025), $4923.0 (Q2 2025), and $2.3 million (Q4 2024), per Business Quant data.